

The Role of the Microbiome in Health and Disease

Jakob Begun

Mater Hospital Brisbane

Mater Research Institute - University of Queensland

research.mater.org.au

There are 100 billion stars in the Andromeda galaxy...

...and 100 billion galaxies in the known universe.

But there are 100 million times as many bacteria on earth as there are stars in the universe

The microbiome is hot





Pub Med References



The taxonomic tree of life



What is the human microbiome



- Microbial community colonising humans
 over 10 trillion organisms
 - Majority of microbiome mass localised within the gut ~ 2 kg
- By DNA content we are >90% microbe and <10% H. sapiens = human holobiont
- Complex interactions with the epithelium, metabolism, immune system, hormonal axes, and nervous system
 - A dynamic relationship to human health

Studying the human microbiome

- Historically viewed through the lens of culture dependent methods and microscopic observation
- Primarily in context of disease and identification of pathogens
- Successful approach for diagnosis and treatment



Culture independent investigation

- Advent of next generation sequencing and bioinformatics has revolutionised the field
 - 16S rRNA allows selective identification of bacterial species
 - Metagenomic approaches provide detailed views of microbial genomes
 - New sequence based approaches for studying the virome and mycobiome









A dynamic microbiome

- The microbiome is a dynamic community
- Significant impact of environmental exposures
- Significant changes with age



Ottman, N., et al., Front Cell Infect Microbiol, 2012. 2: p. 104

Microbiome associations with disease

- Alterations in microbiome composition have been associated with many human diseases and states of health
 - Metabolic disease diabetes, heart disease
 - Cancer bowel cancer, melanoma, hepatocellular carcinoma, lung cancer
 - *Neurologic/psychiatric Parkinson's, anxiety/depression, Autism*
 - Inflammatory diseases rheumatological, pulmonary, genitourinary, neurologic, autoimmune disease
 - Gastrointestinal disease irritable bowel syndrome, Coeliac disease, inflammatory bowel disease
- Focus on the gut microbiome

Metabolic outputs of the microbiome

- Gut microbiota utilise insoluble fibre, mucus, and non-absorbed carbohydrates, protein and fat as energy sources
- Metabolic outputs vary as a function of the microbial composition and diet
- Produce a variety of secondary metabolites
- Metabolise drugs

Gut-Brain Axis



• Bi-directional signalling between the CNS and the gut micorbiome

• CNS \rightarrow Gut

• Motility, secretion, intestinal permeability

• Gut \rightarrow CNS

- Modulation of neurotransmitter release by the gut and direct microbial production
- Modulation of endocrine and immune signalling

Clarke, G., et al. Mol Endocrinol, 2014. 28(8): p. 1221-38.

Microbiome in rodents

- Natural behaviours of mice (e.g BALB/c impaired sociality and exaggerated caution)
 - Altered in the germ free state
 - Can be manipulated through microbiome transfer from different strains
- Antibiotic treatment can cause behavioural changes and changes in stress hormone levels
- Probiotic studies in animals can reduce anxiety/depression
 - Lactobacillus rhamnosus directly stimulates vagus nerve
- Gut derived serotinin production influenced by the microbiome composition Bruce-Keller, A.JBiol Psychiatry, 2018. **83**(3): p. 214-223.

Microbiome - Autism Spectrum Disorder

- ASD is increasing in incidence (as high as 1 in 45)
 - Higher incidence in developed world
 - GI symptoms are prominent in ASD individuals
- In animal models manipulation of the microbiome can result in Autism like behaviours
- In human studies the microbiome signature of ASD is distinct
 - Decreased Bacteroidetes/Firmicutes ratio
 - Decreased SCFA production, and carbohydrate fermentation
 - Confounded by diet
 - Small trial with oral vancomycin and minocycline showed some efficacy signal

Vuong, H.E. and E.Y. Hsiao, Biol Psychiatry, 2017. 81(5): p. 411-423.

Worldwide burden of IBD



Crohn's disease incidence

Ulcerative colitis incidence

- Worldwide prevalence ~400/100,000 (~30M patients)
- Incidence in Australia 29.3/100,000 → Approximately 85,000 patients diagnosed with IBD
- Current treatment paradigms consist primarily of immunosuppressive therapy including potent biologic therapy

Ng, S.C., et al. The Lancet, 2017. 390(10114): p. 2769-2778.

15

The current model of IBD pathogenesis

Multiple hits:

- Genetics
- Dietary factors
- Environmental factors
- Microbial changes









Microbial "dysbiosis" associated with IBD



Multiple studies show increased Firmicute abundance and decreased Bacteriodites **Decreased** microbial diversity in patients with IBD

Gevers et al Cell Host Micro 2014. 15: 382-392

Manipulation of microbiome in IBD

- Antibiotics are effective in luminal and perianal Crohn's disease
- Faecal microbiota transplantation(FMT) is effective at inducing remission in ulcerative colitis
- "Intensive" regimen = 5 enemas per week x 8 weeks

	Faecal microbiota transplantation (n=41)	Placebo (n=40)	Risk ratio (95% Cl)	p value
Primary outcome				
Steroid-free clinical remission and endoscopic remission or response*	11 (27%)	3 (8%)	3.6 (1.1–11.9)	0.021
Secondary outcomes				
Steroid-free clinical remission†	18 (44%)	8 (20%)	2.2 (1.1-4.5)	0.021
Steroid-free clinical response‡	22 (54%)	9 (23%)	2.4 (1.3-4.5)	0.004
Steroid-free endoscopic remission§	5 (12%)	3 (8%)	1.6 (0.4–6.4)	0.48
Steroid-free endoscopic response¶	13 (32%)	4 (10%)	3.2 (1.1-8.9)	0.016



Paramsothy S, Kamm MA, et al. The Lancet 2017

Effect of diet on Microbiome in IBD



The Crohn's Disease Exclusion Diet...

Phase 1 Mandatory foods

Protein-rich foods



Unlimited intake of fresh chicken breast minimum of

1 apple/day peeled

Allowed foods

2 eggs/day

Protein-rich foods



One portion once a week of fresh lean fish replacing the

Rice no odles without preserva-Rice flour for baking

White rice unlimited

1 avo cado/day not more than 5 ripe strawberries/day

1 slice of melon/day



2 tomatoes/day 2 cucumbers/day peeled

1 carrot/day Freshspinach 3 lettuce leaves once daily

Foods that are not on the list of mandatory or allowed foods are disallowed

Disallowed foods



Meats and fish processed. Seafood Red meat, pork, turkey, other parts of the chicken Soy products Dairy products Ice-cream

Non-dairy milk beverages Frozen potatoes All other flours

Corn



Wheat product breakfast Gluten free products not





Frozen vegetables Looks Asparqus Artichoke

All other vegetables not mentioned as allowed

Phase 2

Mandatory foods







2 bananas/dav 1 apple/day peeled



chicken breast minimum of

2 eggs/dav

One portion once a week of

fresh lean fish replacing the

One can of tuna once a week Red meat is not

recommended. Please avoid.

or beans 15 cup of dry, Quinoa (unlimited) 35 cup of oatmeal (allowing

Rice noodles without

Rice flour for baking

15 sweet potato/day

Whole grain bread 1 slice/day

Lentils, peas, chickpeas

Carbohydrate-rich foods

Allowed foods





2 tomatoes/day or 6 cherry 2 cucumbers/day (peeled)

1 carrot/day

Fresh spinach

Zucchini, fresh mushrooms broccoli or cauliflower (but

From week 10, all vegetables

Foods that are not on the list of mandatory or allowed foods are disallowed

Disallowed foods

Dried fruits

All other fruits





Red meat, pork, turkey, other parts of the chicken Dairy products

Non-dairy milk beverages

Seafood

Ice-cream



All other flours



Frozen vegetables Leeks Artichoke



5 ripe strawberries/day

Pear, peach or kiwi/day can

10 blueberries or ½ cup can

From week 10, all fruits



change in community composition from baseline

week 0 to week 6

week 0 to week 12



CDED associated with:

- Increase in beneficial Clostridia family
- Decreased in harmful Proteobacteria
- This change in microbiome composition is associated with clinical response





EEN

. Actinobacteria:

III. Proteobacteria:

II. Clostridia:

CDED

Actinobacteria:

III. Proteobacteria:

II. Clostridia:

Microbiome as a pharma target

- Historically the market has been dominated by nutraceuticals with a paucity of clinical trials
- Evidence of FMT in C. difficile colitis is established, and IBD is growing with significant interest
 - Openbiome Finch, currently conducting Phase 2 trials in C. difficile
 - Janssen Microbiome Institute targeting IBD, T2D
 - Seres Therapeutics Spore based formulation in Ph 2 trials for UC and CDI
 - *Rebiotix acquired by Ferring Pharmaceuticals CDI*
 - Nextbiotix Bacterial treatment for IBD (F. prau)
- FDA/EMA regulatory pathways

Summary

- New techniques in microbiome research have led to unprecedented detail of human microbiome composition
- Multiple associations between microbiome alterations and disease states
- Functional aspects of these changes remain relatively unexplored and are somewhat limited by existing databases
- Evidence in gastrointestinal disease that targeting the microbiome can treat disease such as IBD



Coupling sequence with big data



16S rRNA sequencing Match OTU reads against database



DNA Library preparation and sequencing Metagenomic sequencing Genome assembly Map onto database Bacterial taxonomy Relative abundance

Gene annotation

A word about the gut microbiome



- Oral cavity contains multiple distinct communities
- Upper GI tract characterized by limited diversity adapted to harsh environment (acidic, bile, digestive enzymes)
- The lower intestine is oxygen poor, nutrient rich, and neutral pH

Sartor, R.B. Gastroenterology, 2008. 134(2): p. 577-94.

Increasing incidence of IBD over time





Talley et al. AJG 2011; 106: S2-S25

Role of individual bacteria in IBD

- Protective effect of bacteria F. prausnitzii
 - Produces the MAM peptide which is NF-*k*B supressive



F. prau abundance post-operatively

Protective effect in a mouse model

Sokol, H., et al., Proc Natl Acad Sci U S A, 2008. 105(43): p. 16731-6.